Trial
NCT00535314
Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Biogen
Collaborators
—
Condition
Malignant Melanoma
Intervention
RTA 402 Dose1
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-31